Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study
- 564 Downloads
Palliative chemotherapy in patients with nonresectable advanced colorectal carcinoma is performed to prolong survival, alleviate tumor-associated symptoms, and maintain or improve health-related quality of life (HRQOL). In this prospective single-center observational study, we assessed HRQOL across the various lines of palliative chemotherapy.
HRQOL data were acquired using the EORTC Quality of Life Questionnaire-C30 (QLQ-C30) questionnaire. The first assessment was performed at the beginning of each chemotherapy line, the second after three cycles, and the third at the end of chemotherapy. Further assessments were conducted during checkups every 3 months in our outpatient unit.
In total, 100 consecutive patients with colorectal carcinoma (mean age 66.4 years; 60 % men) treated with palliative chemotherapy were recruited. Generally, QOL deteriorated constantly across time. Physical functioning, fatigue, pain, dyspnea, and appetite worsened steadily from first-line chemotherapy to the later treatment phase. Global QOL, emotional functioning, and role functioning improved slightly after the end of first-line chemotherapy, deteriorated during second-line chemotherapy to the level of first-line chemotherapy, and further deteriorated in the later treatment phases. In additional analyses, we found the largest differences between patients with and without a treatment response for pain (19.0 vs. 37.2 points) and appetite loss (17.4 vs. 32.7 points).
The individual QOL domains deteriorated constantly across time. Our data indicate that patients undergoing first- and second-line palliative chemotherapy experience stabilization of global QOL and psychosocial symptoms. We also found that unselected patients who achieved a treatment response had a lower symptom burden and better QOL than did patients with progressive disease.
KeywordsAdvanced colorectal cancer Quality of life Palliative chemotherapy Electronic patient-reported outcome monitoring
We would like to thank Bettina Buchbauer Mag, MSc. and Ina Pühringer Mag, MSc for their contribution to the data collection.
The study was partly funded by the Forschungsförderungsverein Oberösterreichische Krebshilfe, an independent and non-profit association with the aim of cancer research, cancer prevention, and counseling. The funding source had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Conflict of interest
The authors declare that they have no competing interests.
- 3.de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15(2):808–815PubMedGoogle Scholar
- 5.Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30PubMedCrossRefGoogle Scholar
- 6.Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539–1544PubMedCrossRefGoogle Scholar
- 8.Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011–2019PubMedCrossRefGoogle Scholar
- 13.ESMO Guidelines Working Group, Van Cutsem EJ (2007) Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 18(Suppl 2):ii25–ii26Google Scholar
- 18.Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, et al. (2008) Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 26(22):3702–3708PubMedCrossRefGoogle Scholar
- 21.Outcomes of cancer treatment for technology assessment and cancer treatment guidelines (1996) American Society of Clinical Oncology. J Clin Oncol 14(2):671–679Google Scholar
- 23.Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, et al. (2009) Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 27(11):1822–1828PubMedCrossRefGoogle Scholar
- 24.Farkkila N, Sintonen H, Saarto T, Jarvinen H, Hanninen J, Taari K, et al. (2013) Health-related quality of life in colorectal cancer. Color Dis Off J Assoc Coloproctol G B Irel 15(5):e215–e222Google Scholar